News ArticleSTOCKHOLM (EGMN) - Coupling everolimus with exemestane has produced such dramatic disease control in women with advanced hormone resistant, estrogen receptor-positive breast cancer that it is expected to transform the management of these patients.A preplanned interim analysis of the phase III BOLERO-2 trial found that everolimus (Afinitor) increased the primary end point of progression-free survival, by local assessment, from a median of 2.8 months with exemestane (Aromasin) alone to...